Articles
| Open Access |
DOI: UNVEILING THE CRISIS: THE GLOBAL CHALLENGE OF ANTIBIOTIC DRUG RESISTANCE
Vinita Lahkar , Department Pharmacy Practice, National Institute of Pharmaceutical Education and Research (Niper), Guwahati, Assam, IndiaAbstract
Antibiotic drug resistance has emerged as a critical global challenge, posing a substantial threat to public health, medical treatments, and healthcare systems worldwide. This paper delves into the multifaceted dimensions of antibiotic drug resistance, encompassing its underlying mechanisms, the factors driving its spread, and the far-reaching consequences it engenders. By analyzing the intricate interplay between microbial evolution, inappropriate antibiotic usage, and the lack of novel drug development, this study aims to shed light on the urgency of addressing this crisis. Furthermore, potential strategies and interventions to mitigate antibiotic drug resistance are explored, emphasizing the collaborative efforts required across medical, governmental, and societal domains. The paper underscores the need for a comprehensive and sustained approach to combat this global challenge, safeguarding the effectiveness of antibiotics for current and future generations.
Keywords
Antibiotic resistance, drug-resistant infections, microbial evolution
References
Drug Resistance at the US National Library of Medicine Medical Subject Headings (MeSH).
Levy SB. From tragedy the antibiotic era is born. In: Levy SB, ed. The Antibiotic paradox: How the Misuse of Antibiotics Destroy Their Curative Power, 2nd ed. Cambridge, MA: Perseus Publishing: 2002.pp.1-14.
Rammelkamp M. Resistances of Staphylococcus aureus to the action of penicillin.Proc R Soc Exp Biol Med 1942:51:386-389.
Jaffe HW. Biddle JW. Johnson SR. Wiesner PJ. Infections due to penicillinases-producing Neisseria gonorrhoeae in the United States: 1976-1980. J Infect Dis 1981; 144:191-197.
Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis 1993; 17:1078-1079.
Lowy FD. Medical progress: Staphylococcus aureus infections. N Engl J Med 1998; 339:520-532.
Foster TJ, The Staphylococcus aureus “Superbug”. J Clin Invest 2004; 114:1693-1696.
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S,Rieder H, Binkin N, Dye C, Williams R, and Raviglione M. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344:1294-1303.
Seppala H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of erythromycin: link to introduced erythromycin resistance in Group A streptococci. Clin Infect Dis 1995; 21:1378-1385.
Huovinen P. Macrolide-resistance Group A streptococcus now in the United States. N Engl J Med 2002; 346:1243-1244.
Nuorti JP, Butler JC, Crutcher JM, Guevara R, Welch D, Holder P, Elliot JA. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338:1861-1868.
Article Statistics
Copyright License
Copyright (c) 2023 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.